Microbot Medical Inc logo

Microbot Medical Inc(MBOT)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$0.98
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for MBOT

11/13/2026: MBOT (1-star) is currently NOT-A-BUY. Pass it for now.

Microbot Medical Inc is a micro-cap medical device company specializing in single-use robotic systems for minimally invasive endovascular procedures. The company's primary strength lies in its innovative LIBERTY platform, which offers a differentiated disposable alternative to capital-intensive legacy surgical robots. Its primary growth opportunity centers on expanding commercial adoption within office-scale labs and securing international distribution partnerships. However, the firm faces material execution, dilution, and competitive risks given its early revenue stage and the dominance of medtech giants. The stock is best suited for speculative growth investors willing to monitor regulatory milestones, cash burn rates, and initial commercial traction closely.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitWhile operating in a high-growth surgical robotics sector, the company is still in its early commercialization phase.
Momentum investorStrong fit while signal remains positiveLow float and micro-cap status can attract sharp speculative trading momentum around regulatory and partnership news.
Value investorWeak fitThe lack of consistent earnings and current pre-revenue status makes traditional value metrics inapplicable.
Dividend investorWeak fitThe company pays no dividends and retains all capital to fund clinical and commercial development.
Low-risk investorWeak fitHigh share price volatility and pre-commercial execution risks present substantial capital loss potential.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighMicro-cap clinical-stage status frequently induces sharp, news-driven stock price swings.
Valuation riskHighValuations are driven by future expectations rather than current earnings or cash flows.
Competition risk (legacy medtech giants)HighWell-funded competitors possess dominant hospital networks and established device ecosystems.
Business qualityMediumInnovative IP is offset by early commercial maturity and lack of operating scale.
Dividend incomeLow / noneNo cash distribution is provided to equity holders.
Execution riskHighSuccess relies heavily on navigating commercial adoption, hospital procurement, and clinical scaling.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 65.73M USD
Price to earnings Ratio -
1Y Target Price 5.38
Price to earnings Ratio -
1Y Target Price 5.38
Volume (30-day avg) 926.2K shares
Beta 1.03
52 Weeks Range 0.93 - 2.85
Updated Date 11/15/2026
52 Weeks Range 0.93 - 2.85
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -0.25

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Medical Devices

BUY participation
62.5%
Active BUY / eligible
5 / 8
30-Day BUY Count Change
+3

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Choppy
PRICE STABILITY

Choppy

The stock has experienced frequent reversals and pronounced short-term price swings.

Analysis of Past Performance

Type Stock
Historic Profit 41.28%
Avg. Invested days 20
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 3.0
Stock Returns Performance Upturn Returns Performance icon 3.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
MBOT receives a 2-star rating, supported by solid analyst coverage. The rating is constrained by weak unit economics, soft quantitative characteristics, and weak price momentum.

Company Fundamentals

★★★★★
MBOT has moderate overall fundamentals (3 stars), with moderate financial health, soft growth momentum, and moderate ownership. In FY2025 versus FY2024, growth and ownership metrics are mixed: negative earnings growth (-14.8%), soft cash generation (FCF margin 0.0%), slightly negative revenue growth (+0.0%).

Financial Health Rating

★★★★★
MBOT's financial health is supported by strong efficiency, including operating-expense and cost-of-revenue discipline (opex 0.0% of revenue). Profitability is weak (1 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
MBOT's growth profile is soft, with the least-weak measure being revenue growth at +0.0% FY2025 versus FY2024. By comparison, while earnings growth (-14.8%, negative) and free-cash-flow growth (-48.1%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 16.4% (soft) and 100.0% of outstanding shares are publicly tradable (strong). Insider ownership of 1.22% provides only moderate management-shareholder alignment.

Top 5 Institutional Investors

Vanguard Capital Management, LLC 4.33%
Mitsubishi UFJ Asset Management Co.,Ltd 1.89%
BlackRock Inc 1.34%
Geode Capital Management, LLC 1.25%
UBS Group AG 1.20%

Unit Economics (Per $1K Revenue)

★★★★★
MBOT generates approximately $-0 of gross profit, $-0 of operating income, and $-0 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Weak margins explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
MBOT has a liquid profile. Weak momentum is the primary drawback, while soft valuation.

Style Classification

Quality Focused

Small / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Endoluminal Robotic Systems & DisposablesFuture sales of the LIBERTY robotic system consoles and recurring revenue from single-use sterile accessories.The company aims to transition from a research-stage enterprise into a commercial medical device vendor generating revenue from hardware and disposable kits.

Valuation

Trailing PE -
Forward PE 31.75
Enterprise Value -686.29K
Price to Sales(TTM) 189.98
Enterprise Value -686.29K
Price to Sales(TTM) 189.98
Enterprise Value to Revenue 7.77
Enterprise Value to EBITDA -0.89
Shares Outstanding 67.16M
Shares Floating 67.16M
Shares Outstanding 67.16M
Shares Floating 67.16M
Percent Insiders 1.22
Percent Institutions 16.36

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.